C Zhou, X Li, Q Wang, G Gao, Y Zhang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
AC O'farrell, SD Shnyder, G Marston… - British journal of …, 2013 - Wiley Online Library
Molecular and non‐invasive imaging are rapidly emerging fields in preclinical cancer drug discovery. This is driven by the need to develop more efficacious and safer treatments, the …
DG McEwan, D Popovic, A Gubas, S Terawaki… - Molecular cell, 2015 - cell.com
The lysosome is the final destination for degradation of endocytic cargo, plasma membrane constituents, and intracellular components sequestered by macroautophagy. Fusion of …
MJ Lee, SY Albert, AK Gardino, AM Heijink, PK Sorger… - Cell, 2012 - cell.com
Crosstalk and complexity within signaling pathways and their perturbation by oncogenes limit component-by-component approaches to understanding human disease. Network …
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
Y Shiota, M Elbadawy, K Suzuki, R Tsunedomi… - Biomedicine & …, 2023 - Elsevier
Canine primary lung cancer (cPLC) is a rare malignant tumor in dogs, and exhibits poor prognosis. Effective therapeutic drugs against cPLC have not been established yet. Also …
CT Karadedou, AR Gomes, J Chen, M Petkovic, KK Ho… - Oncogene, 2012 - nature.com
Vascular endothelial growth factor (VEGF) has a central role in breast cancer development and progression, but the mechanisms that control its expression are poorly understood …
M2 polarized tumor-associated macrophages (TAMs) have a multifunctional role in cancer initiation, progression, metastasis, and contribute to chemotherapeutic resistance. Therefore …
NS Hanafy, NAAM Aziz, SSA El‐Hddad… - Archiv der …, 2023 - Wiley Online Library
Abstract Novel thiazolidine‐2, 4‐diones have been developed and estimated as conjoint inhibitors of EGFRT790M and VEGFR‐2 against HCT‐116, MCF‐7, A549, and HepG2 cells …